Evaluating liquid biopsy biomarkers for early detection of brain metastasis: A systematic review. Yu J, Paterson C, Davies P, Palmer JC, Higgins JPT, Kurian KM. Neurooncol Pract. 2025 Mar 18;12(4):600-617. doi: 10.1093/nop/npaf032. PMID: 40814421; PMCID: PMC12349767.

Brain multi-omic Mendelian randomisation to identify novel drug targets for gliomagenesis. Thornton ZA, Andrews LJ, Zhao H, Zheng J, Paternoster L, Robinson JW, Kurian KM. Hum Mol Genet. 2025 Jan 29;34(2):178-192. doi: 10.1093/hmg/ddae168. PMID: 39565278; PMCID: PMC11780873.

Defining the recommended gray zone in O6-methylguanine-DNA methyltransferase promoter methylation pyrosequencing reporting: A robust, translatable method to implement new EANO guidelines. Taylor P, Cruickshank G, Wildman J, Doyle G, Whittaker E, Walker S, McKeeve C, Faulkner C, Yarram-Smith L, White P, Kurian KM. Neurooncol Adv. 2025 Mar 22;7(1):vdaf061. doi: 10.1093/noajnl/vdaf061. PMID: 40444102; PMCID: PMC12121717.

The tumour microenvironment of pilocytic astrocytoma evolves over time via enrichment for microglia. Stone TJ, Pickles JC, Ogunbiyi O, Yasin SA, Taylor CA, Ahmed SW, Chalker J, Dryden C, Slodkowska I, Pang E, Kristiansen M, Williams R, Tutill H, Williams CA, Madhan GK, Forrest L, Brooks T, Hubank M, Hughes D, Proszek P, Pietka G, Peat E, Hargrave D, Jacques TS. Acta Neuropathol Commun. 2025 Feb 13;13(1):30. doi: 10.1186/s40478-024-01922-9. PMID: 39948623; PMCID: PMC11823165.

The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant. Le Rhun E, Bink A, Felsberg J, Gramatzki D, Brandner S, Benhamida JK, Wick A, Tonn JC, Mohme M, Tabatabai G, Capper D, Snuderl M, Razis E, Ronellenfitsch MW, Neidert N, Ng HK, Pohl U, Bale T, Quach S, Rieger D, Schüller U, Onken J, Drüschler K, Maurage CA, Regli L, Healy E, Graham M, Hortobagyi T, Paine S, Bridges L, Lausova T, Medici V, Sievers P, Schrimpf D, Wick W, Sahm F, Reifenberger G, von Deimling A, Weller M. Neuro Oncol. 2025 Jul 30;27(6):1519-1535. doi: 10.1093/neuonc/noaf015. PMID: 39842935; PMCID: PMC12309718.

Anatomic Staging of H3 G34-Mutant Diffuse Hemispheric Glioma. Akeret K, Padevit L, Reifenberger G, von Deimling A, Weller M, Le Rhun E; H3 G34 DHG Study Group. Neurology. 2025 Aug 12;105(3):e213861. doi: 10.1212/WNL.0000000000213861. Epub 2025 Jul 10. PMID: 40638885.

Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes. Sievers P, Arora S, Hielscher T, Savran D, Schrimpf D, Banan R, Vonhören D, Pusch S, Sill M, Appay R, Wirsching HG, Hortobagyi T, Dohmen H, Acker T, Kohlhof-Meinecke P, Schweizer L, Wefers AK, Harter PN, Hartmann C, Beschorner R, Schittenhelm J, Behling F, Tabatabai G, Mawrin C, Snuderl M, Maas SLN, Wesseling P, Brandner S, Korshunov A, Ratliff M, Krieg SM, Wick W, Jones DTW, Pfister SM, Holland EC, von Deimling A, Szulzewsky F, Sahm F. Neuro Oncol. 2025 Oct 14;27(9):2326-2340. doi: 10.1093/neuonc/noaf105. PMID: 40249111; PMCID: PMC12526046.

Testing Meningiomas With Methylation Arrays: Insights and Recommendations From a Large Single-Centre Study. Ruiz F, Rispoli R, Jaunmuktane Z, Merve A, D’Antona L, Dutt M, Sahm F, Brandner S. Neuropathol Appl Neurobiol. 2025;51(3):e70018. doi: 10.1111/nan.70018. PMID: 40356449; PMCID: PMC12070139.

Charting the Single-Cell and Spatial Landscape of IDH-Wildtype Glioblastoma with GBmap. Ruiz-Moreno C, Salas SM, Samuelsson E, Minaeva M, Ibarra I, Grillo M, Brandner S, Roy A, Forsberg-Nilsson K, Kranendonk MEG, Theis FJ, Nilsson M, Stunnenberg HG.  Neuro Oncol. 2025 May 2:noaf113. doi: 10.1093/neuonc/noaf113. Epub ahead of print. PMID: 40312969.

A unified model for Duchenne muscular dystrophy gene involvement in cancer: context-dependent tumour suppression and oncogenicity. Machado L, Jones L, Divakar S, Naidoo M, Anthony K. FEBS Open Bio. 2025 Aug 20. doi: 10.1002/2211-5463.70109. Epub ahead of print. PMID: 40832923.

Disruption of DNA methylation underpins the neuroinflammation induced by targeted CNS radiotherapy. Millner TO, Panday P, Xiao Y, Nicholson JG, Boot JR, Arpe Z, Stevens PA, Rahman NN, Zhang X, Mein C, Kitchen N, McEvoy AW, McKintosh E, McKenna GS, Paraskevopoulos D, Zabet NR, Lewis R, Badodi S, Marino S. Brain. 2025 Sep 3;148(9):3137-3152. doi: 10.1093/brain/awaf163. PMID: 40298030; PMCID: PMC12404709.

Extrachromosomal DNA-Driven Oncogene Spatial Heterogeneity and Evolution in Glioblastoma.  Noorani I, Haughey M, Luebeck J, Rowan A, Grönroos E, Terenzi F, Wong IT, Pradella D, Lisi M, Kittel J, Sharma N, Bailey C, Weeden CE, Bell DM, Joo E, Barbè V, Jones MG, Hung KL, Nye EL, Green M, Meader L, Norton EJ, Fabian M, Kanu N, Jamal-Hanjani M, Santarius T, Ventura A, Nicoll JAR, Boche D, Chang HY, Bafna V, Huang W, Mischel PS, Swanton C, Werner B. Cancer Discov. 2025 Sep 8:OF1-OF18. doi: 10.1158/2159-8290.CD-24-1555. Epub ahead of print. PMID: 40920091.

The invasion phenotypes of glioblastoma depend on plastic and reprogrammable cell states. Doroszko M, Stockgard R, Uppman I, Heinold J, Voukelatou F, Mangukiya HB, Millner TO, Skeppås M, Ballester Bravo M, Elgendy R, Berglund M, Elfineh L, Krona C, Kundu S, Koltowska K, Marino S, Larsson I, Nelander S. Nat Commun. 2025 Jul 19;16(1):6662. doi: 10.1038/s41467-025-61999-1. PMID: 40683881; PMCID: PMC12276355.

The Spectrum of IDH- and H3-Wildtype High-Grade Glioma Subgroups Occurring across Teenage and Young Adult Patient Populations. Pereira R, Mackay A, Grabovska Y, Bradley A, Bloom T, Nicoll J, Boche D, Procter J, Maybury M, Schagen J, Walker L, Roncaroli F, Karabatsou K, Ogunbiyi O, van Dalen T, Sidpra J, Rossi S, Miele E, Ziegler DS, Shi Z, Jacques TS, Hargrave D, Zebian B, Bleil C, Yates J, Norton E, Mandeville H, Creak A, Welsh L, Marshall L, Carceller F, Vaidya SJ, Reisz Z, Al-Sarraj S, Mastronuzzi A, Carai A, Vinci M, Kurian KM, Ng HK, Brandner S, Jones C, Clarke M. Clin Cancer Res. 2025 Aug 1;31(15):3259-3275. doi: 10.1158/1078-0432.CCR-24-1256. PMID: 40063504; PMCID: PMC12314528.

Role of somatostatin receptor 2 (SSTR2) in pituitary adenomas. Power Y, Liu J, Rehman U, Kjerimi A, Schartinger V, Counsell N, Starup-Hansen J, Newall N, Lund VJ, Mohyeldin A, Fernandez-Miranda JC, Lavezo J, Patel ZM, Nayak JV, Hwang PH, Brandner S, Marcus H, West RB, Lechner M. Clin Transl Med. 2025 Aug;15(8):e70435. doi: 10.1002/ctm2.70435. PMID: 40770587; PMCID: PMC12328241.

Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumors.Dampier CH, Shah N, Galbraith K, Ebrahimi A, Neto OLA, Abdullaev Z, Alexandrescu S, Andreiuolo F, Armstrong T, Baker T, Cathcart S, Chung HJ, Cimino PJ, Conway KS, Cotter J, Costa FD, Dazelle K, Etminam N, Ferman SE, Fernandes I, Ferrone CK, Gilani A, Gilbert M, Gregory J, Ketchum C, Lee HS, Lee I, Lopes MBS, Mao Q, Marshall MS, McCord M, Neill SG, Nirschl JJ, Ozer BH, Paulus W, Penas-Prado M, Prinz M, Pytel P, Quezado M, Raffeld M, Rajan S, Ratliff M, Reifenberger G, Robinson L, Schittenhelm J, Schrimpf D, Singh O, Thomas C, Thomas D, Thomas-Ogunniyi J, Toland A, Turakulov R, Vaubel R, Wadhwani N, Wu J, Giannini C, Snuderl M, Brandner S, von Deimling A, Aldape K.  Neurooncol Adv. 2025 Jul 19;7(1):vdaf089. doi: 10.1093/noajnl/vdaf089. PMID: 40735274; PMCID: PMC12305539.

Outcome-associated factors in a molecularly defined cohort of central neurocytoma. Krech M, Muench A, Teichmann D, Kuzman P, Suwala AK, Ippen FM, Müther M, Weber KJ, Wenger-Alakmeh K, Onken J, Vajkoczy P, Behling F, May SA, Ntoulias G, Krauss JK, Atallah O, Esmaeilzadeh M, Mueller WC, Heppner FL, Radbruch H, Dittmayer C, Stenzel W, Koch A, Capper D, Kaul D, Paulus W, Plate KH, Steinbach JP, Czabanka M, Beschorner R, von Deimling A, Bockmayr M, Neumann JE, Brandner S, Krieger T, Hartmann C, Thomas C, Schweizer L. Acta Neuropathol. 2025 Jun 11;149(1):61. doi: 10.1007/s00401-025-02894-3. PMID: 40498174; PMCID: PMC12158839.

Iatrogenic Alzheimer’s disease in recipients of cadaveric pituitary-derived growth hormone. Banerjee G, Farmer SF, Hyare H, Jaunmuktane Z, Mead S, Ryan NS, Schott JM, Werring DJ, Rudge P, Collinge J. Nat Med. 2024 Feb;30(2):394-402. doi: 10.1038/s41591-023-02729-2. Epub 2024 Jan 29. PMID: 38287166; PMCID: PMC10878974.

Delineating the mechanisms of cerebellar degeneration in paediatric and adult primary mitochondrial disease. Smith LA, Olkhova EA, Lax NZ, Ng YS, Taylor RW, Gorman GS, Erskine D, McFarland R. Acta Neuropathol. 2025 May 30;149(1):53. doi: 10.1007/s00401-025-02891-6. PMID: 40445405; PMCID: PMC12125081.

A comprehensive spatiotemporal map of dystrophin isoform expression in the developing and adult human brain. Catapano F, Alkharji R, Chambers D, Singh S, Aghaeipour A, Malhotra J, Ferretti P, Phadke R, Muntoni F. Acta Neuropathol Commun. 2025 May 21;13(1):110. doi: 10.1186/s40478-025-01996-z. PMID: 40400011; PMCID: PMC12096690.

Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease. van Olst L, Simonton B, Edwards AJ, Forsyth AV, Boles J, Jamshidi P, Watson T, Shepard N, Krainc T, Argue BM, Zhang Z, Kuruvilla J, Camp L, Li M, Xu H, Norman JL, Cahan J, Vassar R, Chen J, Castellani RJ, Nicoll JA, Boche D, Gate D. Nat Med. 2025 May;31(5):1604-1616. doi: 10.1038/s41591-025-03574-1. Epub 2025 Mar 6. Erratum in: Nat Med. 2025 May;31(5):1712. doi: 10.1038/s41591-025-03664-0. PMID: 40050704; PMCID: PMC12092304.

Spatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis reveals mitochondrial abnormalities despite disease-related interferon-driven signature. Syntakas AE, Kartawinata M, Evans NML, Nguyen HD, Papadopoulou C, Obaidi MA, Pilkington C, Glackin Y, Mahony CB, Croft AP, Eaton S, Cortina-Borja M, Ogunbiyi O, Merve A, Wedderburn LR, Wilkinson MGL; JDCBS. Ann Rheum Dis. 2025 Oct;84(10):1706-1720. doi: 10.1016/j.ard.2025.07.015. Epub 2025 Aug 9. PMID: 40784813.

Ribogenesis boosts controlled by HEATR1-MYC interplay promote transition into brain tumour growth. Diaz LR, Gil-Ranedo J, Jaworek KJ, Nsek N, Marques JP, Costa E, Hilton DA, Bieluczyk H, Warrington O, Hanemann CO, Futschik ME, Bossing T, Barros CS. EMBO Rep. 2024 Jan;25(1):168-197. doi: 10.1038/s44319-023-00017-1. Epub 2024 Jan 15. PMID: 38225354; PMCID: PMC10897169.

IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy. Tanner G, Barrow R, Ajaib S, Al-Jabri M, Ahmed N, Pollock S, Finetti M, Rippaus N, Bruns AF, Syed K, Poulter JA, Matthews L, Hughes T, Wilson E, Johnson C, Varn FS, Brüning-Richardson A, Hogg C, Droop A, Gusnanto A, Care MA, Cutillo L, Westhead DR, Short SC, Jenkinson MD, Brodbelt A, Chakrabarty A, Ismail A, Verhaak RGW, Stead LF. Genome Biol. 2024 Feb 7;25(1):45. doi: 10.1186/s13059-024-03172-3. PMID: 38326875; PMCID: PMC10848526.

Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression. Apps JR, Gonzalez-Meljem JM, Guiho R, Pickles JC, Prince E, Schwalbe E, Joshi N, Stone TJ, Ogunbiyi O, Chalker J, Bassey A, Otto G, Davies R, Hughes D, Brandner S, Tan E, Lee V, Hayhurst C, Kline C, Castellano S, Hankinson T, Deutschbein T, Jacques TS, Martinez-Barbera JP. Acta Neuropathol Commun. 2024 Aug 10;12(1):127. doi: 10.1186/s40478-024-01838-4. PMID: 39127699; PMCID: PMC11316312.

Evaluating circulating tumour cell enrichment techniques to establish an appropriate method for clinical application in glioblastomas. Barber HR, Perks CM, Kurian KM. Front Neurol. 2024 Feb 28;15:1358531. doi: 10.3389/fneur.2024.1358531. PMID: 38481938; PMCID: PMC10932969.

Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours. Dave F, Herrera K, Lockley A, van de Weijer LL, Henderson S, Sofela AA, Hook L, Adams CL, Ercolano E, Hilton DA, Maze EA, Kurian KM, Ammoun S, Hanemann CO. Oncogene. 2024 Oct;43(41):3049-3061. doi: 10.1038/s41388-024-03131-z. Epub 2024 Aug 23. Erratum in: Oncogene. 2024 Oct;43(41):3080. doi: 10.1038/s41388-024-03177-z. PMID: 39179860; PMCID: PMC11458476

Genomic landscape and actionable mutations of brain metastases derived from non-small cell lung cancer: A systematic review. Andrews LJ, Thornton ZA, Saleh R, Dawson S, Short SC, Daly R, Higgins JPT, Davies P, Kurian KM. Neurooncol Adv. 2023 Nov 24;5(1):vdad145. doi: 10.1093/noajnl/vdad145. PMID: 38130901; PMCID: PMC10734675.

Identification of a putative molecular subtype of adult-type diffuse astrocytoma with recurrent MAPK pathway alterations. Sievers P, Bielle F, Göbel K, Schrimpf D, Nichelli L, Mathon B, Appay R, Boldt HB, Dohmen H, Selignow C, Acker T, Vicha A, Martinetto H, Schweizer L, Schüller U, Brandner S, Wesseling P, Schmid S, Capper D, Abdullaev Z, Aldape K, Korshunov A, Krieg SM, Wick W, Pfister SM, von Deimling A, Reuss DE, Jones DTW, Sahm F. Acta Neuropathol. 2024 Jul 18;148(1):7. doi: 10.1007/s00401-024-02766-2. PMID: 39026106; PMCID: PMC11258072.

Oncogenic extrachromosomal DNA identification using whole-genome sequencing from formalin-fixed glioblastomas. Noorani I, Luebeck J, Rowan A, Grönroos E, Barbe V, Fabian M, Nicoll JAR, Boche D, Bafna V, Mischel PS, Swanton C. Ann Oncol. 2024 Jun;35(6):570-573. doi: 10.1016/j.annonc.2024.03.008. Epub 2024 Mar 28. PMID: 38555024.

Large language models as a diagnostic support tool in neuropathology. Hewitt KJ, Wiest IC, Carrero ZI, Bejan L, Millner TO, Brandner S, Kather JN. J Pathol Clin Res. 2024 Nov;10(6):e70009. doi: 10.1002/2056-4538.70009. PMID: 39505569; PMCID: PMC11540532.

Carbon dot-based fluorescent antibody nanoprobes as brain tumour glioblastoma diagnostics. Ghirardello M, Shyam R, Liu X, Garcia-Millan T, Sittel I, Ramos-Soriano J, Kurian KM, Galan MC. Nanoscale Adv. 2022 Mar 3;4(7):1770-1778. doi: 10.1039/d2na00060a. PMID: 35434521; PMCID: PMC8962998.

Decision making for health-related research outcomes that alter diagnosis: A model from paediatric brain tumours. Pickles JC, Aquilina K, Chalker J, Dahl C, Devadass A, Mankad K, Merve A, Ahmed M, Nicoll JAR, Bloom T, Hilton DA, Sebire NJ, Hargrave D, Jacques TS. Neuropathol Appl Neurobiol. 2024 Aug;50(4):e12994. doi: 10.1111/nan.12994. PMID: 38982613.

Delineating selective vulnerability of inhibitory interneurons in Alpers’ syndrome. Smith LA, Erskine D, Blain A, Taylor RW, McFarland R, Lax NZ. Neuropathol Appl Neurobiol. 2022 Oct;48(6):e12833. doi: 10.1111/nan.12833. Epub 2022 Jul 19. PMID: 35790454; PMCID: PMC9546160.

A reassessment of spinal cord pathology in severe infantile spinal muscular atrophy: Reassessment of spinal cord pathology. Allardyce H, Lawrence BD, Crawford TO, Sumner CJ, Parson SH. Neuropathol Appl Neurobiol. 2024 Oct;50(5):e13013. doi: 10.1111/nan.13013. PMID: 39449271.